Vitiligo is a chronic autoimmune disease with evidence of CTLA-4 involvement. We are performing a pilot study for the treatment of new onset or actively progressing vitiligo with abatacept to determine if weekly self-injections of medication lead to clinical improvement in vitiligo lesions.
1 Primary · 5 Secondary · Reporting Duration: 32 weeks
10 Total Participants · 1 Treatment Group
Primary Treatment: intervention group · No Placebo Group · Phase 1
Age 18+ · All Participants · 5 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
|18 - 65||100.0%|
|Brigham and Women's Hospital||100.0%|